Table 10. Paediatric secondary outcomes*.
| Outcome | Studies contributing data | MgSO4 | Control | RR | LCL | UCL | p† |
| Dichotomous follow-up outcomes | |||||||
| Blind | 9,10,12,13 | 92/1,332 (6.9%) | 128/1,383 (9.3%) | 0.83 | 0.65 | 1.06 | 0.99 |
| Deaf | 9,10,11,12,13 | 83/1,094 (7.6%) | 83/1,167 (7.1%) | 1.10 | 0.83 | 1.47 | 0.99 |
| Developmental delay: any | 9,10,12,13 | 674/1,985 (34.0%) | 706/2,027 (34.8%) | 0.99 | 0.91 | 1.08 | 0.86 |
| Gross motor dysfunction: any | 9,10,13 | 239/1,707 (14.0%) | 279/1,715 (16.3%) | 0.85 | 0.72 | 1.00 | 0.47 |
| Gross motor dysfunction: moderate or severe | 9,10,13 | 55/1,707 (3.2%) | 70/1,715 (4.1%) | 0.78 | 0.55 | 1.11 | 0.69 |
| Neurosensory disability: any | 9,10,11,12,13 | 795/2,283 (34.8%) | 851/2,339 (36.4%) | 0.98 | 0.90 | 1.05 | 0.65 |
| Major neurosensory disability | 9,10,12,13 | 404/2,222 (18.2%) | 427/2,277 (18.8%) | 1.00 | 0.88 | 1.13 | 0.43 |
| Death or any neurosensory disability | 9,10,11,12,13 | 1,228/3,046 (40.3%) | 1,271/3,085 (41.2%) | 0.99 | 0.93 | 1.05 | 0.09 |
| Death or major neurosensory disability | 9,10,11,12,13 | 839/3,046 (27.5%) | 848/3,085 (27.5%) | 1.01 | 0.93 | 1.10 | 0.13 |
| Death or moderate/severe motor dysfunction | 9,10,13 | 281/2,170 (12.9%) | 312/2,220 (14.1%) | 0.91 | 0.78 | 1.06 | 0.40 |
| Continuous follow-up outcomes | Mean (SE) | Mean (SE) | Mean difference | LCL | UCL | p† | |
| Weight z-score§ | 9,10 | −0.33 (0.04) (n = 823) | −0.38 (0.04) (n = 781) | 0.04 | −0.09 | 0.16 | 0.55 |
| Length/height z-score | 9,10 | −0.72 (0.05) (n = 708) | −0.66 (0.06) (n = 653) | −0.06 | −0.21 | 0.09 | 0.34 |
| Head circumference§ | 9,10 | 48.6 (0.07) (n = 779) | 48.5 (0.07) (n = 732) | 0.1 | −0.1 | 0.3 | 0.24 |
Abbreviations: LCL, lower confidence limit; RR, relative risk; SE, standard error; UCL, upper confidence limit. The trials included are as follows: 9 = Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4), 10 = PREterm brain protection by MAGnesium sulphate (PREMAG), 11 = Magnesium and Neurologic Endpoints Trial (MAGNET), 12 = MAGnesium sulphate for Prevention of Eclampsia (MAGPIE), and 13 = Beneficial Effects of Antenatal Magnesium Sulfate (BEAM).
*Overall results from 1-stage individual participant data (IPD).
†Heterogeneity p-values for 1-stage analyses.
§Adjusted for age and sex.